Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Trial of TTI-621 for Patients With Hematologic Malignancies

Complete title: A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refarctory Hematologic Malignancies

Research Study Number 20162887
 
Principal Investigator Mary-Elizabeth Percival
 
Phase I

Research Study Description

Multicenter, open-label, Phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20162887
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Hematologic Malignancies; Neoplasms; Immunotherapy

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials